• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Novartis trial results could spell trouble for Regeneron

June 21, 2017 By Sarah Faulkner

NovartisHead-to-head late-stage clinical trials published on Tuesday showed that a Novartis (NYSE:NVS) drug to treat patients with neovascular age-related macular degeneration doesn’t need to be injected as frequently as a rival drug from competitor Regeneron (NSDQ:REGN).

Analysts reportedly said the data gives Novartis’ treatment, RTH258, a competitive edge compared to its rival therapies.

The trials showed RTH258 worked as well as Regeneron’s Eylea and that slightly more than half the patients needed doses every 12 weeks, compared to every 8 weeks for Regeneron’s drug.

Although the data seemed to be a bad sign for Regeneron, its shares soared 6.7% to $503.59.

Geoffrey Porges, a Leerink Partners analyst, told Reuters that the results remove uncertainty for Regeneron investors who were looking to capitalize on the positive sales trajectory for the company’s recently-approved treatment for severe atopic dermatitis, Dupixent.

Eylea has fueled Regeneron’s growth since 2011, but the therapy’s sales have slowed recently, due largely to competition from rival drugs, and now the company is betting on Dupixent.

He also said that it’s possible that the potential negative impact of Novartis’ data was already priced into the Regeneron stock.

But Jefferies analysts called the trial results “a significant differentiator and competitive advantage for RTH258,” according to the newswire.

Reducing the number of injections a patient has to endure could also give RTH258 a boost over Lucentis, an eye drug that Roche (PINK:RHHBY) markets in the U.S. and Novartis sells elsewhere. Patients who are treated with Lucentis usually need doses every 4 weeks.

Novartis reportedly expects annual sales for RTH258 to top $1 billion.

“It exceeds our expectations and we’re looking forward to filing in 2018” Vas Narasimhan, Novartis’s drug development chief, told Reuters.

The company said it hoped to see 40% or more of patients responding well to injections every 12 weeks.

“Now that we see it well into the 52 to 57% range, we feel very good about the result,” Narasimhan said.

Allergan (NYSE:AGN) is also hoping that reduced injection frequency will score a win for its investigational medicine Abicipar. The company is set to release data from Abicipar trials in 2018.

Material from Reuters was used in this report. 

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Optical/Ophthalmic, Pharmaceuticals, Wall Street Beat Tagged With: Allergan, Novartis, Regeneron, Roche

IN CASE YOU MISSED IT

  • Tandem Diabetes Care wins CE mark for Mobi insulin pump with Control-IQ+ technology
  • Glooko adds chief strategy officer to chief medical officer’s title
  • Cordis launches 10,000-patient registry for drug-eluting balloon
  • Senseonics opens $50M public offering, $25M private placement with Abbott
  • Study links Abbott CGM use to lower risk of hospitalizations due to heart complications

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS